Skip to main content

Table 3 Adverse events during the 2 weeks before discharge

From: Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin

 

non-Dula (n = 38)

Dula (n = 38)

p

Hypoglycemic events, n (%)

 Severe Hypoglycemia

0 (0)

1 (3)

0.53

 hypoglycemia

7 (18)

5 (13)

0.31

Elevation of amylase, n (%)

2 (5)

2 (5)

1.00

Elevation of lipase, n (%)

3 (8)

1 (3)

0.30

Constipation, n (%)

12 (32)

14 (37)

0.20

Nausea, n (%)

1 (3)

3 (8)

0.23

Vomiting, n (%)

0 (0)

1 (3)

0.31

Anorexia, n (%)

3 (8)

4 (11)

0.60

Diarrhea, n (%)

2 (5)

0 (0)

0.15